{
    "name": "inebilizumab",
    "comment": "Rx",
    "other_names": [
        "Uplizna",
        "inebilizumab-cdon"
    ],
    "classes": [
        "Monoclonal Antibodies"
    ],
    "source": "https://reference.medscape.com/drug/uplizna-inebilizumab-4000023",
    "pregnancy": {
        "common": [
            "Humanized IgG1 monoclonal antibody and immunoglobulins are known to cross the placental barrier",
            "Data are not available on developmental risk associated with use in pregnant females; however, transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other B-cell depleting antibodies during pregnancy",
            "The potential duration of B-cell depletion in such infants, and the impact of B-cell depletion on vaccine safety and effectiveness, is unknown"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Females of childbearing potential should use contraception during therapy and for 6 months after the last infusion"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "Administration to mice q3days throughout organogenesis and lactation resulted in depletion of B cells and persistent reductions in immune function (even following repletion of B cells and lasting into adulthood) in offspring"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data are not available on presence in human milk, effects on breastfed infants, or on milk production",
            "Human IgG is excreted in human milk, and the potential for absorption of inebilizumab to lead to B-cell depletion in the breastfed infant is unknown"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "History of life-threatening infusion reaction to inebilizumab",
                "Active HBV infection",
                "Active or untreated latent TB"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Progressive and prolonged hypogammaglobulinemia may occur; monitor levels of quantitative serum immunoglobulins during treatment and until B-cell repletion after discontinuation of therapy, especially in patients with opportunistic or recurrent infections; consider discontinuing if low IgG or IgM develops or a serious infection",
                "Based on animal data, can cause fetal harm owing to B-cell lymphopenia"
            ],
            "specific": [
                {
                    "type": "Infusion reactions",
                    "description": [
                        "Can cause infusion reactions, which can include headache, nausea, somnolence, dyspnea, fever, myalgia, rash, or other signs or symptoms",
                        "Reactions are most common with initial infusion, but were also observed during subsequent infusions",
                        "Premedication with IV corticosteroid, antihistamine, and antipyretic required before every infusion",
                        "For life-threatening infusion reactions, immediately and permanently discontinue and administer appropriate supportive treatment",
                        "For less severe infusion reactions, management may involve temporarily stopping infusion, reducing infusion rate, and/or administering symptomatic treatment"
                    ]
                },
                {
                    "type": "Infections",
                    "description": [
                        "Increased risk infections observed with other B-cell-depleting therapies",
                        "Risks include additive effects if coadministered with other immunosuppressants, HBV reactivation, progressive multifocal leukoencephalopathy, TB reactivation, or risk from live virus administration"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Immunosuppressive drugs",
                        "Coadministration with immunosuppressant drugs, including systemic corticosteroids, may increase risk of infection",
                        "Vaccines",
                        "Administer all needed vaccines at least 4 weeks before initiating inebilizumab",
                        "Vaccination with live-attenuated or live vaccines is not recommended during treatment and until B-cell repletion",
                        "Vaccination of infants born to mothers treated during pregnancy",
                        "Do not administer live or live-attenuated vaccines before confirming recovery of B-cell counts in the infant",
                        "Depletion of B cells in these exposed infants may increase the risks from live or live-attenuated vaccines",
                        "Nonlive vaccines, as indicated, may be administered before recovery from B-cell and immunoglobulin level depletion; consider consultation with a qualified specialist to assess whether a protective immune response was mounted"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "inebilizumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "inebilizumab, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "inebilizumab, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "inebilizumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "inebilizumab, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "inebilizumab, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "upadacitinib",
            "description": {
                "common": "inebilizumab, upadacitinib.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efgartigimod alfa",
            "description": {
                "common": "efgartigimod alfa will decrease the level or effect of inebilizumab by  receptor binding competition. Use Caution/Monitor. Coadministration of efgartigimod with medications that bind to the human neonatal Fc receptor may lower systemic exposures and effectiveness of such medications. Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. If long-term use of such medications is essential, consider discontinuing efgartigimod and using alternative therapies."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "inebilizumab and isavuconazonium sulfate both decrease  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and inebilizumab both increase  immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered"
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Urinary tract infection",
            "percent": "11"
        },
        {
            "name": "Arthralgia",
            "percent": "10"
        },
        {
            "name": "Infusion",
            "percent": "9.3"
        },
        {
            "name": "related reaction",
            "percent": "8"
        },
        {
            "name": "first dose",
            "percent": "7"
        },
        {
            "name": "Headache",
            "percent": "1-1.5"
        },
        {
            "name": "Back pain",
            "percent": "109"
        },
        {
            "name": "Decreased neutrophils",
            "percent": "6.9"
        },
        {
            "name": "x",
            "percent": null
        },
        {
            "name": "L",
            "percent": null
        }
    ]
}